Special Report

Published in:
Volume 6 / Year 2017 / Issue 2

Interchangeability of biosimilars in the US and around the world

Page: 97-8

Abstract: In this paper, differences across the world are highlighted when it comes to the interchangeability of biosimilars. The lack of harmonization makes it difficult for biosimilars makers and could… Read More »

Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US

Author(s): , , ,
Page: 89-96

Abstract: Kinase inhibitors form the largest class of novel anticancer drugs. To date, more than 20 kinase inhibitors have been approved for clinical use. Lengthy patent rights keep the cost… Read More »

Go Back Print